MARKET

TERN

TERN

Terns Pharmaceuticals, Inc.
NASDAQ
52.81
+2.81
+5.61%
Opening 14:30 03/25 EDT
OPEN
52.62
PREV CLOSE
50.00
HIGH
52.88
LOW
52.59
VOLUME
72.80M
TURNOVER
--
52 WEEK HIGH
52.88
52 WEEK LOW
1.865
MARKET CAP
5.74B
P/E (TTM)
-51.1776
1D
5D
1M
3M
1Y
5Y
1D
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
PR Newswire · 3h ago
Morning News Wrap-Up 3/25/26: Today’s Biggest Stock Market Stories!
TipRanks · 4h ago
Investors question premium in Merck's $6.7B deal for Terns Pharma - analyst
Seeking Alpha · 4h ago
Stocks Climb on Hopes of US-Iran Diplomacy
NASDAQ · 4h ago
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B
Seeking Alpha · 4h ago
Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded
TipRanks · 5h ago
BUZZ-U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas
Reuters · 5h ago
Merck’s offer for Terns leaves room for another bidder, says William Blair
TipRanks · 6h ago
More
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Webull offers Terns Pharmaceuticals Inc stock information, including NASDAQ: TERN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TERN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TERN stock methods without spending real money on the virtual paper trading platform.